Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.

Manuel BaaderTom BretschneiderAndre BroermannJoerg F RippmannBirgit StierstorferChristian A KuttruffMichael Mark

Published in: British journal of pharmacology (2018)

Our findings question the role of ATX in the pathogenesis of hepatic fibrosis and the potential of small molecule ATX inhibitors for the treatment of patients with NASH and advanced stages of liver fibrosis.

Keyphrases

liver fibrosis
small molecule
protein protein
cell therapy
risk assessment
human health
bone marrow